During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all ...

James O’Mara is president and chief executive officer at, Neurogastrx, Inc.

The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept would become the first APRIL/BAFF inhibitor for IgAN to make it to the market.

The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall ...

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst ...

The search continues for a new leader for the FDA’s Center for Drug Evaluation and Research after George Tidmarsh resigned on ...

The court’s decision allows Metsera to walk away from its previous acquisition agreement with Pfizer in favor of Novo Nordisk ...

In this episode presented by PII, BioSpace’s head of insights discusses how to relieve clinical trial patients of ...

The FDA awards a second round of Commissioner’s National Priority vouchers to six larger biopharma companies. And this time, ...